Analysis of randomized controlled trials

Epidemiologic Reviews

Volumn 24, Issue 1, 2002, Pages 26-38

  Peduzzi, Peter ^a   Henderson, William ^b   Hartigan, Pamela ^a   Lavori, Philip ^c,d  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; HUMAN; NONBIOLOGICAL MODEL; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD; STATISTICAL MODEL; SURVIVAL; TECHNOLOGY; METHODOLOGY; MULTICENTER STUDY; STATISTICAL ANALYSIS; STATISTICS; TREATMENT OUTCOME;

DATA INTERPRETATION, STATISTICAL; HUMAN; LINEAR MODELS; MULTICENTER STUDIES; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SUPPORT, U.S. GOV'T, NON-P.H.S.; HUMANS;

EID: 0036019107     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/epirev/24.1.26     Document Type: Review

References (105)

1. Intention to treat in clinical trials
2. Statistical considerations in the intent-to-treat principle
3. Beyond intention to treat
4. Comparability of randomized groups
5. Covariate imbalance and random allocation in clinical trials
6. Testing for baseline balance in clinical trials
7. Choosing covariates in the analysis of clinical trials
8. Testing for imbalance of covariates in controlled experiments
9. Choice of covariates in adjustment of treatment effects
10. Covariate adjustment of treatment effects in clinical trials
11. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
12. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
13. Censoring issues in survival analysis
14. Nonparametric estimation from incomplete observations
15. Asymptotically efficient rank invariant test procedures
16. A generalized Wilcoxon test for comparing arbitrarily single-censored samples
17. Regression models and life tables
18. Covariance analysis of censored survival data
19. Validation of a risk function to predict mortality in a VA population with coronary artery disease
20. Partial residuals for the proportional hazards regression model
21. Martingale-based residuals and survival models
22. The robust inference for the proportional hazards model
23. Case-weighted measures of influence for proportional hazards regression
24. Statistical methods for multiple events data in clinical trials
25. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
26. Semiparametric estimation of random effects using the Cox model based on the EM algorithm
27. REML estimation for survival models with frailty
28. Incomplete quality of life data in randomized trials: Missing forms
29. Inference and missing data
30. Correcting for the bias caused by dropouts in hypertension trials
31. Clinical trials in psychiatry: Should protocol deviation censor patient data?
32. Random effects models for longitudinal data
33. Community-based health intervention trials: An overview of methodological issues
34. A multicenter two by two factorial trial of cognitive behavior therapy and aerobic exercise for Gulf War veterans' illnesses: Design of a Veterans Affairs Cooperative Study (CSP #470)
35. Modelling covariance structure in the analysis of repeated measures data
36. Approximate inference in generalized linear mixed models
37. Generalized linear models: A pseudo-likelihood approach
38. Longitudinal data analysis using generalized linear models
39. Modelling the dropout mechanism in repeated-measures studies
40. Informative dropout in longitudinal data analysis
41. The analysis of longitudinal ordinal data with non-random dropout
42. Estimation and comparison of changes in the presence of informative right censoring by modeling the censoring process
43. The randomization theory of experimental inference
44. Modified randomization tests for nonparametric hypotheses
45. Using permutation tests and bootstrap confidence limits to analyze repeated events data from clinical trials
46. Quality-of-life assessment: Can we keep it simple?
47. On substantive research hypotheses, conditional independence graphs and graphical chain models
48. Multi-state models in survival analysis: A study of nephropathy and mortality in diabetes
49. Quality adjusted survival analysis
50. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis
51. Statistical analysis of quality of life data
52. Utility functions for life years and health status
53. Measurement of health-state utilities for economic appraisal: A review
54. Practical guidelines for multiplicity adjustment in clinical trials
55. Clinical trials with multiple outcomes: A statistical perspective on their design, analysis, and interpretation
56. Some statistical methods for multiple endpoints in clinical trials
57. A simple sequentially rejective multiple test procedure
58. A sharper Bonferroni procedure for multiple tests of significance
59. P-value adjustments for multiple tests in multivariate binomial models
60. Assessing laboratory evidence for neoplastic activity
61. Testing the statistical certainty of a response to increasing doses of a drug
62. Procedures for comparing samples with multiple endpoints
63. Use of principal components analysis to develop a composite score as a primary outcome variable in a clinical trial
64. Patient subsets and variation in therapeutic efficacy
65. Testing for qualitative interactions between treatment effects and patient subsets
66. Analysis of clinical trial outcomes: Alternative approaches to subgroup analysis
67. Empirical Bayes estimates of subgroup effects in clinical trials
68. Side reactions in neurotics: I. A comparison of two methods of assessment
69. Measurement of side effects of drugs
70. Survival analysis of adverse effects data in the Beta-Blocker Heart Attack Trial
71. Formal approaches to safety monitoring of clinical trials in life-threatening conditions
72. Guidelines for monitoring efficacy and toxicity responses in clinical trials
73. Group-sequential tests for bivariate response: Interim analysis of clinical trials with both efficacy and safety endpoints
74. Sequential designs for monitoring two endpoints in a clinical trial
75. Confidence intervals for secondary parameters following a sequential test
76. Adjustments for center in multicenter studies: An overview
77. Analysis of data from multi-clinic trials
78. The importance of events per independent variable in proportional hazards analysis. I. Background, goals and general strategy
79. The importance of events per independent variable in multivariable analysis. II. Accuracy and precision of regression estimates
80. A simulation study of the number of events per variable in logistic regression analysis
81. A modified log rank test for highly stratified data
82. Some controversies in planning and analysing multicenter trials
83. Analysis of data from multi-clinic experiments
84. Why analysis of variance is inappropriate for multi-clinic trials
85. Monitoring response variables
86. Group sequential methods in the design and analysis of clinical trials
87. A unifying family of group sequential test designs
88. P-values for tests using a repeated significance test design
89. Estimation following sequential tests
90. Exact confidence intervals following a group sequential test
91. Practical problems in interim analyses, with particular regard to estimation
92. Estimation following group sequential hypothesis testing
93. Stopping rules and estimation problems in clinical trials